|
Nanoviricides,
Inc.
(NNVC) Research Opinion
Last Updated:
July 31, 2008 - 4:17pm EST
NEW YORK--July 31,
2008--Ludlow BioVentures upgrades its research rating on
Nanoviricides, Inc. (OTC: NNVC),
a development stage company that is creating special purpose
nanomaterials for viral therapy,
from
B+ to A-, and
maintains price target of $3.00 per share.
Summary
NanoViricieds
(NNVC) utilizes creative and unique nanomaterials for targeting and
destroying viruses. The company's nanoviricide(TM) drug
candidates are designed to specifically attack enveloped virus
particles and dismantle them, as opposed to vaccines which work to
prevent the delivery of the virus payload. This unique approach makes
NNVC a interesting play in the field of viral therapy, and may hold
some very promising cures to a number of viral infections.
Request
Full NNVC Report Register here
to request a full free copy of NNVC research report.
|
|
Disclosure: This is NOT a solicitation to Buy or Sell any security, but rather is for research purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Ludlow
BioVentures does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. Ludlow
BioVentures, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this
information. In Compliance
with SEC Rule 17B Ludlow BioVentures was NOT compensated for this
research report and distribution, but may or may not be held as a
holding within the Ludlow Biotech Fund, LP, and should be considered a
possible conflict of interest when reviewing this report and
information.
|
Home